Pfizer’s lung cancer portfolio is built on a strong heritage of leadership in targeted therapies. XALKORI was the first targeted therapy approved with a companion diagnostic for any form of lung cancer, establishing Pfizer as a leading innovator in the lung cancer space. LORBRENA builds on this heritage of leadership in ALK+ NSCLC. LORBRENA is the first and only approved third-generation tyrosine kinase inhibitor (TKI) for ALK+ NSCLC and is approved in more than 85 countries, including the US, China, the EU, Japan, and Emerging Markets. LORBRENA has the potential to change the treatment paradigm in ALK+ NSCLC and become a new standard of care. It is currently the second-fastest-growing brand in the Pfizer Oncology portfolio and has priority brand designation. At ASCO 2026, the 7-year follow-up analysis of the pivotal Phase 3 CROWN trial was presented and published, receiving very positive customer and KOL feedback and becoming a key highlight for Pfizer at ASCO. Building on this momentum, the team will continue to amplify the 7-year data while preparing for the next exciting data launch anticipated in 2027. These data are expected to further solidify LORBRENA’s position in ALK+ NSCLC and support peak revenue potential of USD 4 billion. This role will support the continued growth of LORBRENA by leading strategic planning and advancing initiatives that enhance patient experience and treatment adherence.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior